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Abstract
Background: The influence of lipid-lowering therapy on high-density lipoprotein (HDL) is incompletely understood.
We compared the effect of two lipid-lowering strategies on HDL functions and identified some HDL-related proteins.
Methods: Thirty two patients were initially screened and HDLs of 21 patients were finally analyzed. Patients were
randomized to receive atorvastatin 20 mg (n = 11) or atorvastatin 5 mg/ezetimibe 10 mg combination (n = 10) for
8 weeks. The cholesterol efflux capacity and other anti-inflammatory functions were assessed based on HDLs of the
participants before and after treatment. Pre-specified HDL proteins of the same HDL samples were measured.
Results: The post-treatment increase in cholesterol efflux capacities was similar between the groups (35.6% and 34.6%
for mono-therapy and combination, respectively, p = 0.60). Changes in nitric oxide (NO) production, vascular cell
adhesion molecule-1 (VCAM-1) expression, and reactive oxygen species (ROS) production were similar between the
groups. The baseline cholesterol efflux capacity correlated positively with apolipoprotein (apo)A1 and C3, whereas
apoA1 and apoC1 showed inverse associations with VCAM-1 expression. The changes in the cholesterol efflux capacity
were positively correlated with multiple HDL proteins, especially apoA2.
Conclusions: Two regimens increased the cholesterol efflux capacity of HDL comparably. Multiple HDL proteins, not
limited to apoA1, showed a correlation with HDL functions. These results indicate that conventional lipid therapy may
have additional effects on HDL functions with changes in HDL proteins.
Trial registration: ClinicalTrials.gov, number NCT02942602.
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Background
The role of high-density lipoprotein (HDL) in vascular
disease is under active investigation. For instance, the
cholesterol efflux capacity was reported to be inversely
associated with the incidence of cardiovascular events
[1]. However, the clinical implication and role of the
HDL function are not yet fully established. On the other
hand, lowering the low-density lipoprotein-cholesterol
(LDL-C) using statins has been the mainstay of pharma-
cologic therapy aimed at effectively reducing cardiovas-
cular risk [2]. Therefore, most of latest guidelines on
lipid management have adopted statins as first-line
agents [3, 4]. In a recent IMPROVE-IT trial, the applica-
tion of simvastatin 40 mg/ezetimibe 10 mg combination
was shown to reduce cardiovascular risk compared to
using simvastatin 40 mg alone [5]. The addition of ezeti-
mibe 10 mg to ongoing statin therapy is highly effective
in LDL-C-lowering. However, whether the combination
of ezetimibe/statin has differential pleiotropic effect,
such as modification of HDL function, compared to
higher dose statin is not yet completely understood.
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The progress in analytical methodology has enabled
the identification of diverse proteins comprising HDL,
and the list continues to grow. Although traditionally
known to act in lipid transport, numerous HDL proteins
now appear to be involved in other biological functions
such as the acute phase response [6] and inflammation
[7]. The differential expression of proteins including
apolipoprotein (apo)C3 in a diseased condition showed
alteration in other HDL function [8]. Modification of
HDL particles or their proteins is supposed to influence
HDL function. For instance, oxidative stress and inflam-
mation are reported to change the composition of pro-
teins and function of HDL [9]. However, current medical
treatment is insufficient to inhibit atherosclerotic
process related to dysfunctional HDL. Therefore, further
studies of treatment focusing on HDL function would be
recommended. To date, it has been reported that
HDL-related proteins such as apolipoprotein E [10],
paraoxonase-1 [11] or alpha-1 antitrypsin [12] could
be affected by lipid-lowering drugs.
The aim of this study was to compare the effects of two
lipid-lowering strategies, atorvastatin 20 mg and atorva-
statin 5 mg/ezetimibe 10 mg combination, on HDL
functions. Therefore, we examined the influence of the
drugs on HDL: the cholesterol efflux capacity, endothelial
nitric oxide (NO) production, vascular cell adhesion
molecule-1 (VCAM-1) expression, and production of
reactive oxygen species (ROS) by macrophages. Addition-
ally, we attempted to identify the specific HDL proteins
associated with each function. Particularly, we measured
apoA1, apoA2, apoC1, apoC2, and apoC3. We also exam-
ined whether the changes in the HDL functions correlate
with altered HDL proteins following drug treatment.
Methods
Study population
Patients who met the 2013 American College of Cardiology/
American Heart Association criteria for receiving lipid-
lowering therapy were eligible for this study. They consisted
of patients who had a prior history of atherosclerotic cardio-
vascular disease, those who had diabetes mellitus, or high
cardiovascular risk. The patients were statin-naïve or had
discontinued any lipid-lowering agent at least for
3 months before the enrollment unless they had
previous cardiovascular disease. Patients were ex-
cluded if they were pregnant or breast feeding, had a
history of acute cardio- or cerebro-vascular disease
within 3 months before the study, uncontrolled hyper-
tension or diabetes mellitus, thyroid dysfunction,
serum transaminase >2 times the upper limit of normal,
serum creatinine >1.5 mg/dL, an acute or chronic infec-
tion or inflammation, or a history of cancer or adverse
events associated with test drugs including myopathy. All
the patients provided written informed consent.
Study protocol
The present study was a sub-study of an 8-week,
randomized, open-label interventional study that was
approved by Yonsei University Health System, Severance
Hospital, Institutional Review Board (4-2013-0281). This
study was actually a sub-study of a main trial as men-
tioned in the methods section, and we applied the
clinical trial protocol that was used in the main study.
Since our trial followed the protocol, which was revised
after the study began, we included the flowchart of re-
vised version of the protocol (Additional file 1: Figure
S1). At the initial screening visit, the patients were inter-
viewed to obtain their medical histories and then under-
went laboratory assessments. Those who met the criteria
for lipid-lowering therapy were subsequently random-
ized in a 1:1 ratio into two treatment groups for 8 weeks:
atorvastatin 20 mg (Lipitor, Pfizer, New York, NY, USA)
or atorvastatin/ezetimibe 5 mg/10 mg (Lipitor, Pfizer
and Ezetrol, Merck & Co., Whitehouse Station, NJ,
USA). These two regimens were selected on our previ-
ous studies that showed these two regimens reduced
LDL-C levels similarly [13, 14]. Thirty-two patients were
initially screened but 3 of them did not complete the
study: 2 due to refuse to follow-up and 1 due to protocol
violation. Other eight patients were excluded due to
insufficient blood sampling. Because of high censoring
rate in the atorvastatin monotherapy group, enrollment
with unequal allocation was performed to avoid decreas-
ing the power of the comparison. HDL function and
proteins were finally analyzed in 21 patients (11 in
the atorvastatin monotherapy group and 10 in the
combination group; Additional file 1: Figure S1).
Blood sampling and isolation of HDL
Blood samples were collected from the patients on enroll-
ment and after the 8-week drug treatment. The patients
were instructed to fast and avoid alcohol beverages or
smoking for at least 12 h before the collection of the sam-
ples, which were analysed within 4 h. All the analyses were
performed by a local laboratory, certified by the Korean
Society of Laboratory Medicine. The lipid levels were
measured using an auto-analyzer.
HDL was isolated by ultracentrifugation described
below. Briefly, 2 mL of serum sample was transferred
into a 12 mL-ultracentrifuge tube (Polyallomer, Beckman
Coulter Korea Ltd, Seoul, Korea) and then 0.12 g potas-
sium bromide (KBr) and 0.045 g sucrose were added to
be dissolved. Then, 2 mL of solution B (1 mL distilled
water, sodium chloride [NaCl] 0.012 g, and KBr 0.135 g),
4 mL of solution A (distilled water 1 mL plus NaCl
0.012 g plus KBr 0.318 g), and 4 mL of distilled water were
sequentially added. Ultracentrifugation was conducted
using a Beckman Coulter XL-100 K Table Top Ultracen-
trifuge with a Beckman fixed-angle rotor (SW41Ti) for
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18 h at 35,000 rpm. Then, the supernatant, contained the
very low-density lipoprotein and LDL was removed and
HDL was aspirated. The isolated HDL was subsequently
desalted and concentrated with an Amicon 3 k Ultracen-
trifugal Filter device (Merck Millipore Korea, Seoul,
Korea) at 3000 rpm at 4 °C.
In vitro tests of HDL function
The cholesterol efflux assay was performed using a
previously described method [15]. Briefly, the J774 cells
were plated and radiolabeled with 2 μCi of 3H-choel-
sterol/mL for 24 h. For the upregulation of adenosine
triphosphate (ATP)-binding cassette transporter subfam-
ily member A1 (ABCA1), the cells were incubated with
medium containing 0.2% bovine serum albumin (BSA)
and 0.3 mM cyclic adenosine monophosphate (cAMP)
for 2 h. Then, the medium was changed to a medium
containing 0.2% BSA and HDL for 4 h. The experiment
was conducted by treatment the cells with acyl-coenzyme
A:cholesterol acyltransferase inhibitor 2 μg/mL. The chol-
esterol efflux proportion was calculated using the follow-
ing formula: Cholesterol efflux capacity (%) = [3H-
cholesterol (μCi) in medium containing HDL/(3H-choles-
terol {μCi} in medium containing HDL + μCi of 3H-chol-
esterol {μCi} in cells)] x 100. The values were adjusted
based on the efflux capacity of the pooled serum run in
each plate. Each sample was run in duplicate.
The endothelial NO production was assayed as de-
scribed previously [16, 17]. Briefly, the human umbilical
vein endothelial cells were purchased from Lonza (Basel,
Switzerland), grown until the cells had reached 90%
confluency, and then incubated with serum-free medium
overnight. After being treated with 50 μg/mL of HDL,
cells were washed and lysed in 5 mM Tris. After cen-
trifuging the cell lysates, supernatants were trans-
ferred to Amicon 10 kDa cut-off filter tubes (Merck
Millipore Korea) and further centrifuged. Then the
flow-through was collected and nitrite level was mea-
sured using a kit according to manufacturer’s instruc-
tion (Cayman Chemical, Ann Arbor, MI, USA).
The VCAM-1 level was measured by western blotting
[18, 19]. Briefly, the human umbilical vein endothelial
cells were grown and VCAM-1 expression was induced
by 5 ng/mL of tumor necrosis factor-α in serum-free
media overnight. Then, the cells were treated with
50 μg/mL of HDL for 4 h, washed, and lysed in radioim-
munoprecipitation assay buffer supplemented with pro-
tease inhibitor cocktail tablet (Roche Applied Science,
Penzberg, Germany). After that, the total protein con-
centration of cell lysate supernatant was determined,
then 7 μg of protein was loaded, and subsequently sepa-
rated by running the 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). The
proteins were transferred from the gel to a nitrocellulose
membrane and incubated with anti-VCAM-1 (Abcam,
Cambridge, MA, USA) and mouse anti-β-actin anti-
bodies (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). Protein bands were visualized using the
SuperSignal West Pico Chemiluminescent substrate
(ThermoFisher Scientific, Waltham, MA, USA), and
the band intensity was quantified using the ImageJ
software (National Institute of Health, Bethesda, MD,
USA). The VCAM-1 expression was normalized to
the intensity of β–actin, and the levels in cells treated
with each HDL sample were presented as percentages
of untreated cells.
The generation of intracellular ROS was determined
using dichlorodihydrofluorescein diacetate (CM-H2DCFDA,
ThermoFisher Scientific) [20, 21]. After treating J774 cells
with 100 μg/mL of HDL for 24 h, they were stained with
5 μM CM-H2DCFDA in PBS for 24 min at 37 °C, incubated
with or without 100 M hydroperoxide for 20 min, and then
ROS generation was detected using a flow cytometer. The
mean fluorescence intensity was measured in 10,000 cells
using the fluorescein isothiocyanate channel.
Measurement of selected HDL proteins
From preliminary proteomic analysis of HDL samples
based on the protocol we previously reported [22], we
selected five HDL-related proteins that were abundantly
and reproducibly detected: apoA1, apoA2, apoC1, poC2,
and apoC3. The proteins were measured and quantified
as follows. Briefly, the same amount (from 0.5 to 10 μg)
of the HDL samples were separated by 15% SDS-PAGE
and transferred onto polyvinylidene difluoride mem-
branes, which were blocked against nonspecific binding,
and then incubated with primary antibodies against apoA1,
apoA2 (Santa Cruz Biotechnology), apoC1, apoC2
(Abcam), and apoC3 (Academy Bio-Medical Company Inc.,
Houston, TX, USA). Then, the membranes were further
incubated with appropriate horseradish peroxidase-
conjugated bovine anti-mouse or goat anti-rabbit secondary
antibodies (Santa Cruz). The signal was detected using
chemiluminescence with ECL reagent (GE Healthcare,
Piscataway, NJ, USA) and the band intensities were quanti-
fied using the ImageJ software.
Statistical analysis
The clinical and laboratory variables were compared by
the Student’s t-test or chi-square test. A paired t-test
was used to compare the parameters before and after
drug treatment. For the variables showing a skewed
distribution, the Wilcoxon signed-rank test for the
median was used. The Spearman correlation analysis
was used to evaluate the association between the HDL
functional parameters and HDL-related protein levels as
well as the changes of HDL function and those of HDL
protein levels. All the analyses used two-tailed tests with
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a significance level of 0.05. The statistics for the social
sciences version 17.0 software (SPSS Inc, Chicago, IL,
USA) was used for the analyses. This study is registered
with ClinicalTrials.gov, number NCT02942602.
Results
Clinical characteristics and laboratory values
The median age of the study patients was 57 years, and
18 (85%) were males, while three and 13 (14 and 62%,
respectively) had diabetes and coronary artery disease,
respectively. The baseline high-density lipoprotein-
cholesterol (HDL-C) levels were marginally higher in the
atorvastatin group than they were in the combination
group (45 mg/dL and 39 mg/dL, respectively, p = 0.06).
The other clinical and laboratory characteristics were
comparable between both groups (Table 1). After the 8-
week drug treatment, the LDL-C levels were reduced in
both groups, and the median percentage changes were
comparable (-31.6% and -31.1%, respectively, p = 0.57).
Although the HDL-C increased significantly only in
the atorvastatin monotherapy group, the median per-
centage change in the HDL-C did not differ between
the two groups (11.5% and 8.1%, respectively, p = 0.62,
Additional file 1: Table S1).
Changes in HDL function after drug treatment
The baseline median cholesterol efflux capacities were
similar between the atorvastatin and combination groups
(13.1% and 16.4%, respectively, p = 0.32) (Fig 1a). NO and
ROS production, as well as VCAM-1 expression, did not
differ between the two groups (Figs 1c, e, and g). After the
8-week drug treatment, the cholesterol efflux capacity
significantly increased in the atorvastatin, but not in the
combination group (Fig 1a). However, the percentage
change in the capacities did not differ between the groups
(35.6% and 34.6%, respectively, p = 0.60, Fig 1b). The NO
production did not change significantly after treatment in
the monotherapy and combination groups (Fig 1c), and
there were no inter-group difference in the percentage
changes (9.5% and -5.2%, respectively, p = 0.21, Fig 1d).
Furthermore, both groups exhibited no changes in the
VCAM-1 expressions and ROS production after drug
treatment (Figs 1e and g). The percentage changes in the
two functional parameters were similar between the
monotherapy and combination groups (-5.5% and 2.4%,
VCAM-1 expression, p = 0.25; 3.0% and -7.2%, ROS
production, p = 0.43, respectively, Figs 1f and h).
Relationship between changes in HDL function and
HDL-related proteins
The baseline cholesterol efflux capacities were positively
correlated with the apoA1 levels (rho = 0.52, p = 0.02)
and apoC3 (rho = 0.49, p = 0.03), but not with the other
HDL proteins. ApoA1 (rho = -0.73, p = 0.001) and apoC1
(rho = -0.53, p = 0.02) showed negative associations with
the VCAM-1 expression (Table 2), while no proteins
revealed any correlation with NO or ROS production.
Furthermore, drug treatment did not induce significant
changes in all the investigated HDL proteins, while per-
centage changes in expression were similar between the
two groups for each protein (Additional file 1: Figure S2).
However, the change in the cholesterol efflux capacity
had a positive correlation with those of apoA1, apoA2,
apoC1, apoC2, and apoC3. In particular, the correlation
between the changes in capacity and apoA2 was most
obvious (rho = 0.75, p < 0.001). No association was
found between the changes in NO production, VCAM-
1 expression, or ROS production and those of each
HDL protein (Table 3).
Discussion
The following were the major findings of the present
study. 1) The increase in HDL-dependent cholesterol
efflux capacity was similar in the two groups. 2) Both regi-
mens did not change the effect of HDL on NO produc-
tion, VCAM-1 expression, or ROS production. 3) The
cholesterol efflux capacity was positively associated with
apoA1 and apoC3, whereas apoA1 and apoC1 revealed a
negative correlation with VCAM-1 expression. 4) The






Age, years 58 (51, 64) 57 (43, 63) 0.75
Male 9 (82) 9 (90) 1.00
Medical history
Hypertension 8 (73) 6 (60) 0.88
Diabetes mellitus 2 (18) 1 (10) 1.00
LDL-C ≥160 mg/dL 4 (36) 0 (0) 0.12
Smoking 7 (64) 6 (60) 1.00
Coronary artery disease 6 (55) 7 (70) 0.78
Body mass index, kg/m2 24.4 (23.4, 25.6) 25.9 (23.4, 26.5) 0.44
Laboratory values, mg/dL
Total cholesterol 214 (191, 261) 200 (163, 211) 0.17
Triglyceride 187 (125, 341) 120 (105, 184) 0.26
HDL-C 45 (42, 54) 39 (37, 45) 0.06
LDL-C 110 (95, 155) 134 (102, 142) 0.83
Medications
Aspirin 7 (64) 7 (70) 1.00
β-blockers 5 (46) 4 (40) 1.00
Calcium channel blockers 3 (27) 3 (30) 1.00
RAS inhibitors 6 (55) 5 (50) 1.00
Variables are expressed as median (25th percentile, 75th percentile) or number
(%), HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-
cholesterol, RAS renin-angiotensin system
Lee et al. Lipids in Health and Disease  (2017) 16:49 Page 4 of 8
change in cholesterol efflux capacity induced by the
drug treatment was linked to the changes in multiple
HDL proteins, including apoA2. To the best of our
knowledge, this study is the first to report the effect
of a statin/ezetimibe combination and compare two
statin-based regimens on HDL function. Furthermore,
the relationship between drug-induced changes in
HDL function and proteins shown in our study may
provide an insight into the additional pleiotropic ef-
fect of the current lipid-lowering therapy.
A few studies have shown that statins can increase
HDL-dependent cholesterol efflux capacity, including a
14% with simvastatin 40 mg [23] and by 9% with pitavas-
tatin 2 mg [11]. However, it was recently reported that
atorvastatin did not affect cholesterol efflux capacity in
studies using the sera of mice [24] or human [25]. The
reason for the inconsistency in the statin effect on this
HDL function is not clear yet. Interestingly, the choles-
terol efflux has been shown to increase in studies with
statin-induced increase in HDL-C [11, 23], whereas it
decreased when statins lowered HDL-C [24]. In our
study, HDL-C was raised, although not significantly, in
both groups. However, we used the same concentration
of isolated HDL from each subject and, therefore, the
drug effect on the HDL concentration might have been
minimized by our method, and the changes in HDL
function were possibly due to differences in HDL itself.
Ezetimibe has been known to enhance reverse choles-
terol transport and faecal cholesterol excretion [26, 27].
Nevertheless, data on the effect of ezetimibe on HDL
function including cholesterol efflux capacity is ex-
tremely limited. Recently, it was reported in hamsters
that ezetimibe did not change the efflux capacity of the
serum after the adjustment of HDL-C levels [27].
Fig. 1 The parameters of high-density lipoprotein (HDL) function and the percentage changes after drug treatment. a and b) Cholesterol
efflux capacity, c and d nitric oxide (NO) production, e and f vascular cell adhesion molecule-1 (VCAM-1) expression, and g and h
reactive oxygen species (ROS) production
Table 2 Correlation between the parameters of high-density lipoprotein (HDL) function and selected HDL-related proteins
Cholesterol efflux NO production VCAM-1 expression ROS production
rho p rho p rho p rho p
ApoA1 0.52 0.02 -0.10 0.71 -0.73 0.001 0.26 0.35
ApoA2 -0.10 0.67 0.20 0.48 0.14 0.58 0.05 0.85
ApoC1 0.41 0.73 0.14 0.61 -0.53 0.02 0.01 0.98
ApoC2 0.26 0.28 0.08 0.77 -0.38 0.12 -0.09 0.76
ApoC3 0.49 0.03 -0.05 0.86 -0.40 0.10 -0.04 0.89
NO nitric oxide, VCAM vascular cell adhesion molecule, ROS reactive oxygen species
Lee et al. Lipids in Health and Disease  (2017) 16:49 Page 5 of 8
Combination therapy with atorvastatin/ezetimibe has in-
duced percentage changes in the cholesterol efflux cap-
acity similar to that induced by atorvastatin monotherapy.
However, several points have not been clearly understood
by our results. 1) It is not clear whether the increased ef-
flux capacity induced by drug treatment is largely caused
by a primary effect on HDL or secondary effect induced
by changes in the lipid metabolism. 2) Furthermore, if the
observed change is due to a direct effect on HDL, we are
not certain if this is attributable to the effects of ezetimibe
or low-dose atorvastatin.
The two different regimens used in our study did not
affect the anti-inflammatory function of HDL, whereas
they enhanced the cholesterol efflux. Studies evaluating
the relationship between HDL proteins and HDL func-
tions, particularly anti-inflammatory, have been highly
limited. These present results are in agreement with
those of Triolo et al. [23] who evaluated the effect of
simvastatin. Gordon et al. [12] reported that rosuvastatin
increased HDL-related α1-antitrypsin that reduces the
production of tumor necrosis factor-α. In addition,
Green et al. [10] found that statin/niacin combination
reduced HDL-related apoE. Meanwhile, Miyamoto-
Sasaki et al. [11] revealed that HDL-associated
paraoxonase-1 was increased by pitavastatin. Although
we did not focus on paraoxonase-1, this enzyme is
known to suppress proinflammatory response and ROS
production [28, 29], and act as one of the key HDL-
related proteins.
To date, insufficient amount of data exists on the
effects of the drugs on HDL proteins and their relations
to biological function. In the present study, we evaluated
the correlations between the changes in HDL functions
and proteins and identified some relationships. Above
all, the effect of apoA1 on the functions of HDL ob-
served in our study was very similar to previously
reported data. ApoA1 is a major HDL-related protein
[6], which is known to be critical for cholesterol efflux
[30]. Moreover, apoA1 was required for reconstituted
HDL to inhibit the expression of cell adhesion molecules
[31]. In the present study, we discovered that the
changes in apoA2 correlated with drug-induced changes
in the cholesterol efflux capacity. It was demonstrated
that HDL particles containing apoA2 without apoA1
effectively enhanced the cholesterol efflux [32]. In
addition, the ability of free apoA2 to promote cholesterol
efflux was also reported [33] while Remaley et al. [34]
and Sankaranarayanan et al. [35] showed that apoA2
plays a role in the ABCA1- and ABCG1-mediated chol-
esterol efflux, respectively. However, the effect of drug
treatment on apoA2 and its influence on HDL has not
been shown before. Therefore, our results on apoA2
may provide an insight into the additive effect of lipid-
modifying agent that is mediated, at least partly, by
HDL-related proteins.
ApoC1 was negatively correlated with the endothelial
VCAM-1 expression in our study. Studies regarding inves-
tigating the biological role of apoC1 have been very limited,
and the results were inconsistent. It has been demonstrated
that apoC1 increased the lipopolysaccharide-induced in-
flammation [36]. Conversely, apoC1 was reported to inhibit
pro-inflammatory cytokine production in murine immune
cells [37]. Interestingly, the inhibitory effect of HDL on
LPS-induced inflammation was reduced in lecithin-
cholesterol acyltransferase (LCAT)-deficient mice [38]. It is
well known that apoC1 activates LCAT, which is needed
for HDL maturation [39]. Based on this background,
apoC1 may affect vascular inflammation by LCAT activa-
tion and HDL maturation. The role of apoC3 in HDL func-
tion has not been completely established. Only recently,
proteomic analysis of murine HDL identified the correl-
ation between cholesterol efflux capacity and apoC3 [40].
Our study also discovered this association in human HDLs.
Although its clinical relevance is not entirely clear cur-
rently, this association was also validated by the relation-
ship observed between the changes in apoC3 and those of
the cholesterol efflux in our study.
Our study had some potential limitations. First, we
suggested the effect of HDL proteins and the correla-
tions between the drug-induced changes in these pro-
teins and functional changes in the HDL based on
systemic analyses. However, the mechanism underlying
the biological role of HDL proteins in HDL functions
may not have been completely elucidated by this study.
Future studies on the proteins that determine the drug-
induced changes in HDL function may provide further
Table 3 Correlations between the changes in high-density lipoprotein (HDL) function and those of HDL-related proteins
Cholesterol efflux NO production VCAM-1 expression ROS production
rho p rho p rho p rho p
ApoA1 0.59 0.01 0.09 0.75 -0.31 0.22 -0.22 0.43
ApoA2 0.75 <0.001 0.11 0.70 -0.12 0.63 0.45 0.11
ApoC1 0.60 0.01 0.26 0.34 -0.08 0.76 -0.06 0.82
ApoC2 0.46 0.048 0.41 0.14 -0.32 0.21 0.46 0.10
ApoC3 0.59 0.01 0.31 0.29 -0.32 0.20 0.41 0.15
NO nitric oxide, VCAM vascular cell adhesion molecule, ROS reactive oxygen species
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insights. Second, we chose candidate proteins based on
abundancy and reproducibility of the measurement.
Nevertheless, numerous other proteins that have been
currently reported may have additional effects on the
HDL function. For instance, we cannot rule out the
potential of the anti-inflammatory HDL-associated en-
zymes, which may have played a specific role in the in
vitro tests we performed. Third, the drug effect shown
by in vitro experiment may not be extrapolated to in
vivo or clinical outcomes. For a more comprehensive
understanding, testing the drug effect in both hepato-
cytes and other peripheral cells might be helpful. Finally,
total number of our subjects was not sufficiently large.
However, when designing this study, we referred to
those of prior reports that showed drugs-induced
changes of cholesterol efflux in relatively small groups of
patients [12, 13].
Conclusion
Taken together, these results suggest that atorvastatin
monotherapy and the low-dose atorvastatin/ezetimibe
combination similarly promoted the HDL-dependent
cholesterol efflux capacity. Furthermore, the HDL-
related proteins, including but not limited to apoA1,
showed correlations with drug-induced changes as well
as the baseline function of HDL. Our study indicates
that conventional lipid-lowering therapy may have add-
itional pleiotropic effect on HDL function, at least partly,
by the changes of HDL proteins.
Additional file
Additional file 1: Table S1. Changes in lipid profiles after 8-week drug
treatment. Figure S1. CONSORT 2010 flow diagram. Figure S2. Expression
of high-density lipoprotein (HDL)-related proteins before and after drug
treatment. (A) ApoA-I, (B) ApoA-II, (C) ApoC-I, (D) ApoC-II, (E) ApoC-III.
(ZIP 353 kb)
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